Scholar Rock (SRRK) Revenue & Revenue Breakdown
Scholar Rock Revenue Highlights
Scholar Rock Revenue by Period
Scholar Rock Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $33.19M | 76.41% |
| 2021-12-31 | $18.82M | 22.16% |
| 2020-12-31 | $15.40M | -24.83% |
| 2019-12-31 | $20.49M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | -100.00% |
| 2016-12-31 | $379.00K | - |
Scholar Rock generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Scholar Rock Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $11.66M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $33.19M | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | -100.00% |
| 2022-03-31 | $33.19M | 719.78% |
| 2021-12-31 | $4.05M | -25.90% |
| 2021-09-30 | $5.46M | 18.91% |
| 2021-06-30 | $4.59M | -2.40% |
| 2021-03-31 | $4.71M | 37.02% |
| 2020-12-31 | $3.44M | 13.14% |
| 2020-09-30 | $3.04M | -22.13% |
| 2020-06-30 | $3.90M | -22.47% |
| 2020-03-31 | $5.03M | -33.58% |
| 2019-12-31 | $7.57M | 58.63% |
| 2019-09-30 | $4.77M | -5.26% |
| 2019-06-30 | $5.04M | 62.23% |
| 2019-03-31 | $3.11M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Scholar Rock generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Scholar Rock Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARVN | Arvinas | $78.50M | $76.50M |
| RLAY | Relay Therapeutics | $25.55M | - |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| MGTX | MeiraGTx | $14.02M | $282.00K |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| RNA | Avidity Biosciences | $9.56M | $2.04M |
| IKNA | Ikena Oncology | $9.16M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| IGMS | IGM Biosciences | $2.13M | $497.00K |
| PLRX | Pliant Therapeutics | $1.58M | - |
| FIXX | Q32 Bio | $1.16M | - |
| BCEL | Atreca | $770.00K | $80.00K |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| CERE | Cerevel Therapeutics | - | - |
| PASG | Passage Bio | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| SRRK | Scholar Rock | - | - |
SRRK Revenue FAQ
What is Scholar Rock’s yearly revenue?
Scholar Rock's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $33.19M, representing an increase of 76.41% compared to 2021. SRRK's yearly revenue for 2021 was $18.82M, representing an increase of 22.16% compared to 2020.
What is Scholar Rock’s quarterly revenue?
Scholar Rock's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). SRRK's quarterly revenue for Q4 2023 was $11.66M, a 100.00% increase from the previous quarter (Q3 2023), and a -64.87% decrease year-over-year (Q4 2022).
What is Scholar Rock’s revenue growth rate?
Scholar Rock's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.